Merck's Endometrial Cancer Drug Cuts Risk of Death by 32%
Merck presented Phase 3 data for Sac-TMT showing longer survival versus chemotherapy in advanced endometrial cancer. FDA decision is due by June 15, 2027.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Merck said the Phase 3 trial of its experimental drug Sacituzumab Tirumotecan, or Sac-TMT, showed patients with advanced or recurrent endometrial cancer lived longer than those given chemotherapy alone. The findings were presented at the ESMO Congress 2026 alongside new Keytruda data, according to Stocktwits.
The TroFuse-005 study enrolled 776 patients. The risk of death fell 32%, and median overall survival reached 19 months versus 12.1 months with chemotherapy. The drug also cut the risk of progression or death by 41%. Merck shares traded about 3% lower on Monday, their third straight session of losses.
why it matters
The FDA accepted the application for priority review and set a PDUFA date of June 15, 2027. For Merck, oncology remains a core focus, and approval could broaden its pipeline beyond Keytruda. The stock is up more than 32% in 2026, so some expectations are already priced in, according to retail sentiment cited by Stocktwits.
market impact
MRK: positive trial data supports the company's long-term outlook, while short-term shares face pressure after a strong run
tags
instruments
sources
- Merck’s Endometrial Cancer Drug Cuts Risk Of Death By 32% – FDA Decision Due By June 2027 — Stocktwits, 26 October 2026 at 17:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗